Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis

American Journal of Nephrology

Volumn 17, Issue 6, 1997, Pages 505-510

  El Reshaid, Kamel ^a   El Reshaid, Wael ^a   Sugathan, Thattuparambil ^a   Al Mohannadi, Shehab ^b   Sivanandan, Ramier ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b MINISTRY OF HEALTH   (Kuwait)

Author keywords

Parathyroid hormone; Renal osteodystrophy; Vitamin D3

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL;

ADENOMA; ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; CALCITRIOL; CHOLECALCIFEROL; FEMALE; HUMANS; HYPERPARATHYROIDISM; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; RANDOM ALLOCATION; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 0030664584     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000169179     Document Type: Article

References (16)

1. Saarem K, Pedersen JI: 25-Hydroxylation of I-hydroxyvitamin D; in rat and human liver. Biochim Biophvs Acta 1985;840:117-126.
2. Lindenau K, Kokot F, Abendroth K, Futh U, Grossmann I, Schmidt C, Rehse C, Frohling PT: Ten years’ experience in the prevention of renal osteodystrophy by vitamin D prophylaxis: in Norman AW, Schaefer K. Grigoleit HG. Hcrrath DV (eds): Vitamin D: Mollecular. Cellular and Clinical Endocrinology. Berlin, de Gruyter, 1988, pp 787-788.
3. 3 on the bone in patients with renal osteodystrophy. Am J Med 1978:64:101-107.
4. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calciterol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989:321: 274-279.
5. Slatopolsky E, Wecrts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1.25-dihydroxychole-calciferol in uremic patients. J Clin Invest 1984:74:2136-2143.
6. Brandi L, Daugaard H, Tvcdcgaard E, Storm T, Olgaard K: Effects of intravenous 1-hydro-xyvitamin Dj on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron 1989:53:194-200.
7. Brandi L, Daugaard H, Tvedegaard E, Nielsen PK, Egsmose C, Storm T, Olgaard K: Longterm suppression of secondary hyperparathyroidism by intravenous 1-hydroxyvitamin D; in patients on chronic hemodialysis. Am J Nephrol 1992:12:311-318.
8. Kaplowitz N, Eberle D, Yamada T: Hepatic drug metabolism and drug-induced liver disease; in Gitnick G (ed): Current Hepatology. Boston. Houghton Mifflin, 1980. pp 181-211.
9. De Broe ME, Drucke TB, Ritz E: Diagnosis and treatment of aluminum overload in end-stage renal failure patients. Nephrol Dial Transplant 1993(suppl 1): 1-4.
10. Goldsmith SJ: Endocrine system: in Bernier DR, Christian PE, Langan JK (eds): Nuclear Medicine (Technology and Techniques), ed 3. St Louis. Mosby-Yearbook, 1994, pp 222-251.
11. Papapoulos SE, vd Berg H, Frolich M, Valentijin RM: Circulating 1,25-dihydroxycholecalci-ferol after injections of 1-alpha-hydroxychole-calcifcrol in patients on regular hemodialysis. Nephrol Dial Transplant 1988:3:647-650.
12. 3 1,25-dihydroxyvita-min Dj and 25,25-dihydroxyvitamin Ds on parathyroid hormone secretion, adenosine 3,5-monophosphate release, and ultrastructure of parathyroid gland in organ culture. Endocrinology 1979;105:237-245.
13. Canterbury JM, Lerman S, Claflin AJ, Henry H, Norman A, Reiss E: Inhibition of parathyroid hormone secretion by 25-hydroxycholecal-ciferol and 24,25 dihydroxycholecalciferol in the dog. J Clin Endocrinol Metab 1977:44: 1054-1060.
14. 3 derivatives in the treatment of renal bone diseases: Justification and optimal modalities of administration. Nephron 1995;71:254-283.
15. Kurz P, Tsobanclis T, Roth P. et al: Differences in calcium kinetic pattern between CAPD and HD patients. Clin Nephrol 1995:44:255-261.
16. Ljutic D, Cameron JS, Ogg CS, et al: Long-term follow up after total parathyroidectomy without parathyroid reimplantation in chronic renal failue. Q J M ed 1994;87:685-692.